Key Points
- Major shareholder Jennifer Pritzker sold 250,000 ATEC shares at $20.80 for $5.2 million, reducing her stake by 2.19% to 11,145,045 shares, according to an SEC filing.
- ATEC stock traded down about 2.3% to $19.74 on the day, with a market cap of roughly $2.93 billion and trading above its 50- and 200-day moving averages.
- Analysts are largely positive (nine Buys, average target $22), and Alphatec recently beat quarterly estimates with revenue up 30.4% year-over-year and EPS of $0.03.
Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) major shareholder Jennifer Pritzker sold 250,000 shares of the firm's stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $20.80, for a total value of $5,200,000.00. Following the sale, the insider directly owned 11,145,045 shares of the company's stock, valued at $231,816,936. This trade represents a 2.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.
Alphatec Stock Down 2.3%
ATEC stock traded down $0.46 during trading hours on Friday, hitting $19.74. The company's stock had a trading volume of 2,603,589 shares, compared to its average volume of 2,130,456. The stock has a 50 day moving average price of $16.06 and a two-hundred day moving average price of $13.88. Alphatec Holdings, Inc. has a 12 month low of $8.18 and a 12 month high of $21.16. The company has a market capitalization of $2.93 billion, a PE ratio of -17.47 and a beta of 1.17. The company has a quick ratio of 1.77, a current ratio of 2.88 and a debt-to-equity ratio of 23.22.
Alphatec (NASDAQ:ATEC - Get Free Report) last announced its quarterly earnings results on Thursday, October 30th. The medical technology company reported $0.03 earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.09. The company had revenue of $196.50 million during the quarter, compared to analyst estimates of $182.78 million. During the same period in the prior year, the firm earned ($0.28) EPS. Alphatec's quarterly revenue was up 30.4% on a year-over-year basis. Alphatec has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of research analysts recently issued reports on the stock. Barclays raised their target price on shares of Alphatec from $22.00 to $23.00 and gave the company an "overweight" rating in a research note on Monday, November 3rd. Stifel Nicolaus started coverage on Alphatec in a research note on Tuesday, October 28th. They issued a "buy" rating and a $20.00 price objective on the stock. Piper Sandler restated an "overweight" rating and set a $25.00 target price (up previously from $20.00) on shares of Alphatec in a research note on Friday, October 31st. Needham & Company LLC upped their price target on Alphatec from $16.00 to $22.00 and gave the stock a "buy" rating in a report on Friday, October 31st. Finally, Lake Street Capital set a $25.00 price objective on shares of Alphatec and gave the stock a "buy" rating in a research note on Friday, October 31st. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Alphatec has an average rating of "Moderate Buy" and an average target price of $22.00.
Get Our Latest Research Report on Alphatec
Institutional Investors Weigh In On Alphatec
A number of institutional investors have recently bought and sold shares of ATEC. Aster Capital Management DIFC Ltd acquired a new stake in shares of Alphatec during the 3rd quarter valued at about $34,000. Osterweis Capital Management Inc. bought a new stake in Alphatec in the second quarter valued at $37,000. Larson Financial Group LLC bought a new stake in Alphatec during the first quarter worth about $54,000. Nisa Investment Advisors LLC grew its position in Alphatec by 22.4% during the 2nd quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company's stock worth $63,000 after acquiring an additional 1,045 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new position in Alphatec in the 3rd quarter valued at $73,000. Institutional investors and hedge funds own 66.35% of the company's stock.
Alphatec Company Profile
(
Get Free Report)
Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
